Search Results - "Carrillo Infante, Cynthia"
-
1
Optimized management of advanced hepatocellular carcinoma:Four long-lasting responses to sorafenib
Published in World journal of gastroenterology : WJG (21-05-2011)“…The therapeutic options for hepatocellular carcinoma (HCC) have been so far rather inadequate.Sorafenib has shown an overall survival benefit and has become…”
Get full text
Journal Article -
2
Safety of eculizumab in NMOSD and MG: Analysis of the phase 3 studies prevent and regain, and their extensions
Published in Journal of the neurological sciences (01-10-2021)Get full text
Journal Article -
3
Infection Risk in Patients with Complement-Mediated Neurological Disorders Receiving Eculizumab: Findings from Two Phase 3 Studies and Their Extensions in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD) and Acetylcholine-Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis (AChR+ gMG) (1829)
Published in Neurology (14-04-2020)“…Abstract only…”
Get full text
Journal Article -
4
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis
Published in Multiple sclerosis and related disorders (01-04-2020)“…Natalizumab is an effective treatment for multiple sclerosis (MS) and has a well-characterized safety profile, with more than 10 years of postmarketing…”
Get full text
Journal Article -
5
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
Published in The Lancet. Haematology (01-12-2023)“…BACKGROUNDSymptoms of anaemia due to clinically significant extravascular haemolysis can affect patients with paroxysmal nocturnal haemoglobinuria (PNH)…”
Get full text
Journal Article -
6
Real-World Safety and Efficacy of Natalizumab after Switching from Other Disease-Modifying Therapies (DMTs): Data from the Tysabri® Observational Program (TOP) (P2.069)
Published in Neurology (05-04-2016)“…Abstract only…”
Get full text
Journal Article -
7
Abstract 1411: Doxorubicin Triggers Replicative Senescence and Death of Cardiac Progenitor Cells
Published in Circulation (New York, N.Y.) (28-10-2008)“…Abstract only Doxorubicin (DOXO) is a very effective drug for the treatment of neoplastic diseases. However, DOXO causes a cardiomyopathy that leads to…”
Get full text
Journal Article -
8
Abstract 1839: MicroRNA-499 Promotes the Differentiation of Cardiac Progenitor Cells into Myocytes
Published in Circulation (New York, N.Y.) (28-10-2008)“…Abstract only Myocardial regeneration mediated by cardiac progenitor cells (CPCs) results in the partial recovery of the infarcted heart but the newly formed…”
Get full text
Journal Article -
9
Abstract 1491: Notch1 Inhibition Interferes with Differentiation of Glomerular Progenitor Cells into Podocytes
Published in Circulation (New York, N.Y.) (28-10-2008)“…Abstract only The objective of this work was to identify a population of glomerular progenitor cells (GPCs) capable of generating podocytes which are…”
Get full text
Journal Article -
10
Abstract 3422: Asymmetric Division of Human Cardiac Progenitor Cells Involves Immortal DNA Strand Cosegregation
Published in Circulation (New York, N.Y.) (28-10-2008)“…Abstract only The objective of this study was to determine whether asymmetric division of human cardiac progenitor cells (hCPCs) occurs by: random DNA template…”
Get full text
Journal Article -
11
Drug Development-targeted Screening of Leptin Agonist Glycopeptides
Published in International journal of peptide research and therapeutics (01-09-2008)“…A glycosylated dodecapeptide fragment corresponding to the hypothalamus-active cytokine leptin exhibits agonistic properties to the leptin receptor (ObR)…”
Get full text
Journal Article